Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001599298-25-000089
Filing Date
2025-05-01
Accepted
2025-05-01 16:11:31
Documents
65
Period of Report
2025-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q smmt-20250331.htm   iXBRL 10-Q 738380
2 EX-31.1 sum-ex311_20250331xduggan.htm EX-31.1 11878
3 EX-31.2 sum-ex312_20250331xzanganeh.htm EX-31.2 11923
4 EX-31.3 sum-ex313_20250331x10qsoni.htm EX-31.3 11977
5 EX-32.1 sum-ex321_20250331x10q.htm EX-32.1 11142
11 smmt-20250331_g1.jpg GRAPHIC 18976
12 smmt-20250331_g2.jpg GRAPHIC 39642
  Complete submission text file 0001599298-25-000089.txt   4990782

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT smmt-20250331.xsd EX-101.SCH 40840
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT smmt-20250331_cal.xml EX-101.CAL 44417
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT smmt-20250331_def.xml EX-101.DEF 163101
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT smmt-20250331_lab.xml EX-101.LAB 528521
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT smmt-20250331_pre.xml EX-101.PRE 345807
68 EXTRACTED XBRL INSTANCE DOCUMENT smmt-20250331_htm.xml XML 478402
Mailing Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131
Business Address 601 BRICKELL KEY DRIVE SUITE 1000 MIAMI FL 33131 305-203-2034
Summit Therapeutics Inc. (Filer) CIK: 0001599298 (see all company filings)

EIN.: 371979717 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36866 | Film No.: 25903224
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)